Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
1.
J Alzheimers Dis ; 90(1): 233-249, 2022.
Article in English | MEDLINE | ID: covidwho-2274374

ABSTRACT

BACKGROUND: Preliminary work by our center has reported behavior and functional benefits in patients with Alzheimer's disease (AD) following targeted micronutritional supplementation. OBJECTIVE: To build on the existing exploratory research and investigate the impact of these micronutrients on the natural progression of AD in a randomized controlled trial. METHODS: Patients with mild-moderate AD consumed daily 1 g fish oil (of which 500 mg DHA, 150 mg EPA), 22 mg carotenoids (10 mg lutein, 10 mg meso-zeaxanthin, 2 mg zeaxanthin), and 15 mg vitamin E or placebo for 12 months in a double-blind, placebo-controlled, randomized clinical trial. Carotenoids, ω-3FAs, and vitamin E were quantified in blood. Carotenoids were also measured in skin. AD severity was measured using the mini-mental state examination and dementia severity rating scale tools. Behavior, mood, and memory were measured using an informant-based questionnaire. RESULTS: Following 12 months of supplementation, the active group (n = 50) compared to the placebo group (n = 27), demonstrated statistically significant improvements in skin carotenoid measurements, blood carotenoids, ω-3FAs, and vitamin E concentrations (p < 0.05, for all). The active group also performed better in objective measures of AD severity (i.e., memory and mood), with a statistically significant difference reported in the clinical collateral for memory (p < 0.001). CONCLUSION: Exponential increases in the prevalence of AD and its relentless progressive nature is driving the need for interventions that help to ameliorate symptoms and improve quality of life in AD patients. Given the positive outcomes demonstrated in this trial, this combined micronutrient dietary supplement should be considered in the overall management of AD.


Subject(s)
Alzheimer Disease , Fatty Acids, Omega-3 , Humans , Alzheimer Disease/drug therapy , Vitamin E/therapeutic use , Carotenoids/therapeutic use , Quality of Life , Dietary Supplements , Double-Blind Method
2.
Int J Mol Sci ; 23(22)2022 Nov 18.
Article in English | MEDLINE | ID: covidwho-2143226

ABSTRACT

Although pulmonary fibrosis (PF) is considered a rare disease, the incidence thereof has increased steadily in recent years, while a safe and effective cure remains beyond reach. In this study, the potential of tocotrienol-rich fractions (TRF) and carotene to alleviate PF was explored. PF was induced in Sprague-Dawley rats via a single intratracheal bleomycin (BLM) (5 mg/kg) instillation. These rats were subsequently treated with TRF, carotene, pirfenidone (Pir) and nintedanib (Nin) for 28 days via gavage administration, whereafter histopathological performance, biochemical functions and molecular alterations were studied in the lung tissues. Our results showed that TRF, carotene, Nin and Pir all ameliorated PF by reducing inflammation and resisting oxidative stress to varying degrees. The related mechanisms involved the TGF-ß1/Smad, PI3K/Akt and NF-κB signaling pathways. Ultimately, our findings revealed that, when combined with TRF, the therapeutic effects of Nin and Pir on PF were enhanced, indicating that TRF may, indeed, provide promising potential for use in combination therapy in the treatment of PF.


Subject(s)
Pulmonary Fibrosis , Tocotrienols , Rats , Animals , Pulmonary Fibrosis/metabolism , Tocotrienols/pharmacology , Tocotrienols/therapeutic use , Phosphatidylinositol 3-Kinases/metabolism , Rats, Sprague-Dawley , Carotenoids/therapeutic use
3.
Biomed Pharmacother ; 154: 113625, 2022 Oct.
Article in English | MEDLINE | ID: covidwho-2003886

ABSTRACT

The Coronavirus Disease-2019 (COVID-19) pandemic urges researching possibilities for prevention and management of the effects of the virus. Carotenoids are natural phytochemicals of anti-oxidant, anti-inflammatory and immunomodulatory properties and may exert potential in aiding in combatting the pandemic. This review presents the direct and indirect evidence of the health benefits of carotenoids and derivatives based on in vitro and in vivo studies, human clinical trials and epidemiological studies and proposes possible mechanisms of action via which carotenoids may have the capacity to protect against COVID-19 effects. The current evidence provides a rationale for considering carotenoids as natural supportive nutrients via antioxidant activities, including scavenging lipid-soluble radicals, reducing hypoxia-associated superoxide by activating antioxidant enzymes, or suppressing enzymes that produce reactive oxygen species (ROS). Carotenoids may regulate COVID-19 induced over-production of pro-inflammatory cytokines, chemokines, pro-inflammatory enzymes and adhesion molecules by nuclear factor kappa B (NF-κB), renin-angiotensin-aldosterone system (RAS) and interleukins-6- Janus kinase-signal transducer and activator of transcription (IL-6-JAK/STAT) pathways and suppress the polarization of pro-inflammatory M1 macrophage. Moreover, carotenoids may modulate the peroxisome proliferator-activated receptors γ by acting as agonists to alleviate COVID-19 symptoms. They also may potentially block the cellular receptor of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), human angiotensin-converting enzyme 2 (ACE2). These activities may reduce the severity of COVID-19 and flu-like diseases. Thus, carotenoid supplementation may aid in combatting the pandemic, as well as seasonal flu. However, further in vitro, in vivo and in particular long-term clinical trials in COVID-19 patients are needed to evaluate this hypothesis.


Subject(s)
COVID-19 Drug Treatment , Anti-Inflammatory Agents/pharmacology , Anti-Inflammatory Agents/therapeutic use , Antioxidants/pharmacology , Antioxidants/therapeutic use , Carotenoids/pharmacology , Carotenoids/therapeutic use , Humans , Pandemics , SARS-CoV-2
4.
Drug Dev Res ; 82(7): 883-895, 2021 11.
Article in English | MEDLINE | ID: covidwho-1168846

ABSTRACT

The current pandemic forced us to introspect and revisit our armamentarium of medicinal agents which could be life-saving in emergency situations. Oxygen diffusion-enhancing compounds represent one such class of potential therapeutic agents, particularly in ischemic conditions. As rewarding as the name suggests, these agents, represented by the most advanced and first-in-class molecule, trans-sodium crocetinate (TSC), are the subject of intense clinical investigation, including Phase 1b/2b clinical trials for COVID-19. Being a successor of a natural product, crocetin, TSC is being investigated for various cancers as a radiosensitizer owing to its oxygen diffusion enhancement capability. The unique properties of TSC make it a promising therapeutic agent for various ailments such as hemorrhagic shock, stroke, heart attack, among others. The present review outlines various (bio)synthetic strategies, pharmacological aspects, clinical overview and potential therapeutic benefits of crocetin and related compounds including TSC. The recent literature focusing on the delivery aspects of these compounds is covered as well to paint the complete picture to the curious reader. Given the potential TSC holds as a first-in-class agent, small- and/or macromolecular therapeutics based on the core concept of improved oxygen diffusion from blood to the surrounding tissues where it is needed the most, will be developed in future and satisfy the unmet medical need for many diseases and disorders.


Subject(s)
COVID-19/therapy , Carotenoids/therapeutic use , Oxygen Consumption/drug effects , Oxygen Inhalation Therapy/methods , Vitamin A/analogs & derivatives , Animals , Carotenoids/chemical synthesis , Carotenoids/pharmacology , Clinical Trials, Phase I as Topic , Clinical Trials, Phase II as Topic , Diffusion , Humans , Vitamin A/chemical synthesis , Vitamin A/pharmacology , Vitamin A/therapeutic use
5.
J Food Biochem ; 45(5): e13718, 2021 05.
Article in English | MEDLINE | ID: covidwho-1166081

ABSTRACT

The current COVID-19 pandemic is one of the most devastating events in recent history. In the lack of a specific treatment and vaccine for this novel infection, finding effective drugs against this infection is crucial. We suggest the hypothesis that crocin, the main carotenoid of saffron, has the potential to limit the progression and severity of the SARS-CoV2 infection for several reasons: (a) crocin possesses powerful antioxidant properties, (b) crocin can alleviate the uncontrolled cytokine production responsible for acute lung injury, (c) crocin can upregulate PPARγ and downregulate NF-κB expression which leads to a wide range of immunomodulatory and anti-inflammatory effects, and (d) crocin can reduce the viral-induced oxidative stress and downregulates ACE2 expression by activating Nrf2 pathway. We hope our hypothesis, corroborated by preclinical evidence, will inspire further targeted studies to test crocin as a beneficial drug against the SARS-CoV2 infection. PRACTICAL APPLICATIONS: Crocin is a natural antioxidant and the main active carotenoid components of saffron. We suggest the hypothesis that crocin has the potential to limit the progression and severity of the SARS-CoV2 infection because of its antioxidant and anti-inflammatory properties. Furthermore, this compound may prevent viral entry to host cells and reduce SARS-CoV2-induced lung injury. Therefore, we suggest further clinical studies on the effects of crocin against SARS-Cov-2 infection.


Subject(s)
COVID-19 Drug Treatment , Pandemics , Anti-Inflammatory Agents/pharmacology , Carotenoids/pharmacology , Carotenoids/therapeutic use , Humans , RNA, Viral , SARS-CoV-2
SELECTION OF CITATIONS
SEARCH DETAIL